Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono Fires Back to 1.75 Trillion Yen Guesstimate, Puts Opdivo Sales at 126 Billion Yen
Ono Pharmaceutical on April 11 moved to rebut an emerging speculation that its immuno-oncology drug Opdivo (nivolumab) could cost 1.75 trillion yen for its lung cancer indication by unveiling its own sales forecast a month ahead of schedule. In the…
To read the full story
Related Article
- Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
May 12, 2016
- Front-Loaded Price Cuts Necessary for Drugs Like Opdivo: JMA’s Nakagawa
April 7, 2016
- MOF Panel Hears Expert’s Opinions on Opdivo Prices
April 5, 2016
- Pricing Debate Spills Over into MHLW Safety Panel, Member Warns Opdivo Costs Could Jeopardize State Finances
February 22, 2016
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…